Get the Stockscreener App
1.51
1.95%
-0.03
Pre-market:
1.46
-0.05
-3.31%
Ironwood Pharmaceuticals Inc stock is traded at $1.51, with a volume of 1.73M.
It is down -1.95% in the last 24 hours and down -24.88% over the past month.
See More
Previous Close:
$1.54
Open:
$1.52
24h Volume:
1.73M
Relative Volume:
0.59
Market Cap:
$586.50M
Revenue:
$400.57M
Net Income/Loss:
$9.21M
P/E Ratio:
37.75
EPS:
0.04
Net Cash Flow:
$146.36M
1W Performance:
-2.58%
1M Performance:
-24.88%
6M Performance:
-66.96%
1Y Performance:
-82.52%
1-Day Range:
$1.455
$1.575
1-Week Range:
$1.34
$1.605
52-Week Range:
$1.34
$9.23
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
1.51 | 586.50M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
160.06 | 71.67B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 47.44B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.19 | 46.08B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.46 | 18.86B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.36 | 13.97B | 612.78M | -86.37M | -62.91M | -0.87 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Report Prev - GuruFocus.com
Analysts Say You Should Hold Your Position In Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) - Stocks Register
Ironwood Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ironwood Pharmaceuticals, Inc. Class A to Host Earnings Call - ACCESS Newswire
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down - MSN
Ironwood Pharma Delays 10-K Filing Due to Internal Issues - TipRanks
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now? - Insider Monkey
Los Angeles Capital Management LLC Boosts Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - MarketBeat
Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates - MSN
Ironwood Pharmaceuticals (NASDAQ:IRWD) Issues Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Releases Quarterly Earnings Results - MarketBeat
12 Best Small Cap Pharma Stocks to Buy Now - Insider Monkey
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2024 Earnings Call Transcript - Insider Monkey
Ironwood: Q4 Earnings Snapshot - The Herald Review
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ... - Yahoo Finance
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ... By GuruFocus - Investing.com Canada
Ironwood Pharmaceuticals Reports 2024 Financial Results - TipRanks
Investor Network: Ironwood Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ironwood Pharmaceuticals’ Earnings Call: Growth Amid Challenges - TipRanks
Ironwood Pharmaceuticals chief legal officer sells shares worth $68,530 - MSN
Ironwood Pharma stock surges 9% on apraglutide progress, Linzess growth - Investing.com India
Ironwood Pharma stock surges 9% on apraglutide progress, Linzess growth By Investing.com - Investing.com South Africa
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results - TradingView
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance - Business Wire
CIBC Asset Management Inc Takes $53,000 Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Ironwood Pharmaceuticals Inc expected to post earnings of 8 cents a shareEarnings Preview - TradingView
Brokerages Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) PT at $8.60 - Defense World
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call - BioSpace
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Sees Large Growth in Short Interest - MarketBeat
Ironwood Pharmaceuticals Inc (IRWD): A New Perspective - Stocks Register
Ironwood Pharmaceuticals Sets Key Date for 2024 Financial ResultsHere's When to Tune In - StockTitan
FY2025 Earnings Forecast for IRWD Issued By Zacks Research - MarketBeat
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls - MSN
Zacks Research Issues Negative Forecast for IRWD Earnings - MarketBeat
What is Zacks Research’s Estimate for IRWD FY2025 Earnings? - Defense World
Michael Shetzline Sells 41,269 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Sells $244,752.64 in Stock - MarketBeat
Ironwood Pharmaceuticals (IRWD) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Insider Selling: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Insider Sells 12,048 Shares of Stock - MarketBeat
IRONWOOD PHARMACEUTICALS Earnings Preview: Recent $IRWD Insider Trading, Hedge Fund Activity, and More - Nasdaq
Ironwood Pharmaceuticals CEO Thomas A. McCourt sells $244,752 in stock - MSN
Zacks Research Issues Negative Outlook for IRWD Earnings - Defense World
11,869 Shares in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Acquired by SG Americas Securities LLC - Defense World
Ironwood Pharmaceuticals' principal accounting officer sells $21,204 in stock - MSN
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ironwood Pharmaceuticals Inc Stock (IRWD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Silver Ronald | Principal Accounting Officer |
Feb 10 '25 |
Sale |
1.76 |
12,048 |
21,204 |
279,655 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug |
Feb 10 '25 |
Sale |
1.76 |
41,269 |
72,633 |
554,007 |
| John Minardo | Chief Legal Officer |
Feb 10 '25 |
Sale |
1.76 |
38,938 |
68,531 |
408,132 |
| Martini Gregory S. | Chief Financial Officer |
Feb 10 '25 |
Sale |
1.76 |
12,052 |
21,212 |
183,810 |
0.77%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):